Efficacy of Stromal Vascular Fraction and Platelet-Rich Plasma Therapy on Post-COVID-19 Nephrotic Syndrome in Diabetic Type 1 Patient: A Case Report

Authors

  • Karina Karina Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia
  • Imam Rosadi Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Samarinda, Indonesia
  • Grady Krisandi Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
  • Tommy P. Sibuea Faculty of Medicine, Christian University of Indonesia, Jakarta, Indonesia
  • Johannes Albert Biben Hayandra Clinic, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Krista Ekaputri Hayandra Clinic, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Diani Nazma Faculty of Medicine, Trisakti University, Jakarta, Indonesia
  • Azza Maryam Hayandra Clinic, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Siti Sobariah HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Elisa Christina Jaman Hayandra Clinic, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Cecilia Sagita Wibisana Hayandra Clinic, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Jessica Miranda Hayandra Clinic, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Irsyah Afini HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Difky Ernanda HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Tias Widyastuti HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Alfida Zakiyah HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Noor Aini HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia

Keywords:

coronavirus disease 2019, nephrotic syndrome, platelet-rich plasma, stromal vascular fraction

Abstract

Extrapulmonary complications in currently infected or recovered COVID-19 patients is a concerning problem. One of these complications is post-COVID nephrotic syndrome which usually requires anti-inflammatory agent for treatment. Among the various anti-inflammatory agents available, the combination of autologous activated platelet-rich plasma (aaPRP) and stromal vascular fraction (SVF) is a potential breakthrough therapy. It not only exerts an anti-inflammatory effect, but also a regenerative effect. To our knowledge, this is the first report of aaPRP and SVF therapy in post-COVID nephrotic syndrome patient. A 27-year-old type 1 diabetic female patient was admitted to Hayandra Clinic with symptoms of nephrotic syndrome after being recovered from COVID-19. The use of SVF and aaPRP combination therapy showed­­­­­ immediate significant improvement in patient’s overall kidney function and clinical manifestations.

Downloads

Published

2022-05-05